Evolent Health, Inc. EVH
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- +7.50%
- 1 year
- -34.85%
- Open
- 4.26
- Prev close
- 4.25
- Mkt cap
- 486.16M
- Vol
- 1.15M
- Avg vol
- 2.54M
- EPS
- -4.49
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.09
- High
- 4.31
- Forward P/E
- 6.01
- Beta
- 0.73
- Short ratio
- 6.55
- Inst. own
- 108.70%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2025
- 50-d avg
- 9.86
- 200-d avg
- 9.96
- 1y target
- 15.46
News
2 weeks ago defenseworld.net
Analyzing CareCloud (NASDAQ:CCLD) & Evolent Health (NYSE:EVH)
Evolent Health (NYSE: EVH - Get Free Report) and CareCloud (NASDAQ: CCLD - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses…
3 weeks ago prnewswire.com
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release…
3 weeks ago defenseworld.net
Evolent Health, Inc (NYSE:EVH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Evolent Health, Inc (NYSE: EVH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen ratings firms that are covering the company, Marketbeat Ratings reports.…
1 month ago globenewswire.com
TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6
JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6
TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
2 months ago seekingalpha.com
Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming
Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term…
2 months ago defenseworld.net
Dimensional Fund Advisors LP Has $4.08 Million Stock Position in Evolent Health, Inc $EVH
Dimensional Fund Advisors LP reduced its stake in Evolent Health, Inc (NYSE: EVH) by 22.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
-
2 months ago benzinga.com
Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.
-
2 months ago benzinga.com
Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6
Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.
2 months ago marketbeat.com
Evolent Health Q2 Earnings Call Highlights
Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May…
2 months ago seekingalpha.com
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics…
2 months ago zacks.com
Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
-
2 months ago benzinga.com
Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est
Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
-
2 months ago benzinga.com
Evolent Health Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $652.520M Beat $597.997M Estimate
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 120 percent increase over losses of $(0.10) per…
2 months ago prnewswire.com
Evolent Announces Second Quarter 2026 Results
WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through…
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5
TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.
-
3 months ago benzinga.com
Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75
Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $7
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
3 months ago marketwatch.com
Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.
The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.
3 months ago zacks.com
Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now
Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.
3 months ago prnewswire.com
Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026
WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release…
4 months ago zacks.com
Should You Buy Evolent Health (EVH) After Golden Cross?
Evolent Health, Inc (EVH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EVH's 50-day simple moving average crossed above…
-
4 months ago benzinga.com
Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.
4 months ago zacks.com
Strength Seen in Evolent Health (EVH): Can Its 9.5% Jump Turn into More Strength?
Evolent Health (EVH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more…
-
4 months ago benzinga.com
Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
5 months ago benzinga.com
Rumble, Agilon Health And Oscar Health Among Stocks Moving Higher On Thursday
Stocks had mixed performance on Thursday, Dow Jones up 793 points while Nasdaq down 232 points. Rumble rose after $270M deal.
5 months ago 247wallst.com
Agentic AI Powers U.S. Healthcare Stocks
Healthcare payrolls keep climbing, and hospital systems, payers, and clinics are now openly treating agentic AI as the cheapest unit of labor on the market.
-
5 months ago benzinga.com
Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.
5 months ago marketbeat.com
Evolent Health Q1 Earnings Call Highlights
Evolent Health NYSE: EVH reported first-quarter 2026 results that management said were in line with expectations, while reiterating its full-year outlook and highlighting new contract wins, early…
5 months ago seekingalpha.com
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Needham Maintains Buy on Evolent Health, Raises Price Target to $5
Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.
5 months ago zacks.com
Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics…
-
5 months ago benzinga.com
Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est.
Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.400 billion-$2.600 billion vs $2.487 billion estimate.
-
5 months ago benzinga.com
Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate.
Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 133.33 percent decrease over earnings of $0.06…
6 months ago benzinga.com
XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
-
8 months ago benzinga.com
Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.
-
8 months ago benzinga.com
Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.
-
8 months ago benzinga.com
UBS Maintains Buy on Evolent Health, Lowers Price Target to $5
UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.
-
8 months ago benzinga.com
Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $6
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $6.
-
8 months ago benzinga.com
Needham Maintains Buy on Evolent Health, Lowers Price Target to $4
Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $15 to $4.
-
8 months ago benzinga.com
RBC Capital Maintains Sector Perform on Evolent Health, Lowers Price Target to $3
RBC Capital analyst Ryan Halsted maintains Evolent Health (NYSE:EVH) with a Sector Perform and lowers the price target from $5 to $3.
8 months ago benzinga.com
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
8 months ago benzinga.com
This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
-
8 months ago benzinga.com
BTIG Maintains Buy on Evolent Health, Lowers Price Target to $8
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $8.
-
8 months ago benzinga.com
Evolent Health Q4 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $468.719M Beat $468.701M Estimate
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 37.93 percent. This is a 500 percent increase over losses of $(0.02) per…